{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-042508","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2026-09-14T13:29:43+00:00","discovered_at":"2026-09-14T13:31:00.429998+00:00","generated_at":"2026-09-14T13:31:07.726418+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"FDA approves Biofrontera's Ameluz PDT for superficial basal cell carcinoma; launch expected Q4 2026–Q1 2027","bullets":["FDA approved sNDA for Ameluz (aminolevulinic acid) topical gel 10% + BF-RhodoLED lamp for sBCC in adults; first US PDT approved for skin cancer.","Phase 3 trial (187 adults): composite complete response 66% (95/145) with Ameluz PDT vs 5% (2/42) placebo; histological clearance 76% vs 19%.","Estimated US market: 540,000–720,000 sBCC cases/yr (approx. 15–20% of 3.6M BCC cases); existing AK indication retained.","Commercial launch of sBCC indication planned late Q4 2026 through Q1 2027 using existing commercial organization and installed lamp base.","CEO Hermann Luebbert calls approval a defining milestone; expands addressable market and strengthens PDT platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-042508","json":"https://secwatch.observer/filing/0001493152-26-042508.json","markdown":"https://secwatch.observer/filing/0001493152-26-042508.md","text":"https://secwatch.observer/filing/0001493152-26-042508.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315226042508/0001493152-26-042508-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315226042508/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T13:31:07.726418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}